Mindray Bio-Medical Partners with Nanjing Drum Tower Hospital to Boost Clinical Research
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a leading medical equipment provider, has entered...
2024
Qilu Pharmaceutical’s QL1706 Receives NMPA Conditional Approval for Cervical Cancer Treatment
Qilu Pharmaceutical, a Chinese pharmaceutical company, has announced that its combination drug QL1706, comprising iparomlimab...
Study Predicts 2025 Medicare Part D Negotiation Candidates, With Novo Nordisk’s Semaglutide Leading the List
Researchers in the U.S. have compiled a list of drugs that are anticipated to be...
Dupixent Secures Back-to-Back COPD Approvals from US FDA and China NMPA
Regeneron (NASDAQ: REGN), a leading biopharmaceutical company based in the U.S., in collaboration with its...
AbbVie Submits First BLA for c-Met Targeting ADC Telisotuzumab Vedotin to FDA
AbbVie Inc. (NYSE: ABBV), a leading pharmaceutical company in the U.S., has announced the filing...
Whittilong Pharma Secures Over RMB 100 Million in Series B Financing for Modified Drug Development
Whittilong Pharma, a Shanghai-based modified drug development company backed by Shanghai Healthcare Capital (SHC), has...
HOYA Surgical Optics Expands in China with New Artificial Intraocular Lens Facility
HOYA Surgical Optics has established its presence in the Suzhou High-Tech Zone of Jiangsu province,...
Shanghai Pharmaceuticals Partners with SIBPT to Boost Biopharmaceutical R&D and Translation
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has entered into a partnership with the Shanghai...
Shanghai Fosun Pharmaceutical Gets NMPA Clinical Clearance for Lymphoma Drug XS-04
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent pharmaceutical company based...
Shanghai Fosun Pharmaceutical’s SBK010 Stroke Treatment Accepted for NMPA Review
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
3D Medicines’ H1’24 Financials Reflect Increased Comprehensive Loss Amid Revenue Decline
3D Medicines (HKG: 1244), a China-based oncology specialist, has released its financial report for the...
China Sets New Management Measures for Investigator-Initiated Trials in Medical Institutions
The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control...
China Unveils Medical Insurance Eligibility Management System for Designated Healthcare Personnel
The National Healthcare Security Administration (NHSA), National Health Commission, and National Medical Products Administration (NMPA)...
OrbusNeich Medical Group Partners with Abbott’s CSI as Sole Distributor
Shenzhen-based vascular intervention specialist OrbusNeich Medical Group Ltd (HKG: 6929) has announced a significant distribution...
Jacobio Pharma Receives NMPA Approval for Pan-KRAS Inhibitor JAB-23E73 Clinical Trial
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has received approval from the...
AstraZeneca’s Tagrisso Secures FDA Approval for Unresectable Stage III EGFRm NSCLC
AstraZeneca (NASDAQ: AZN, LON: AZN), a UK-based pharmaceutical giant, has announced that it has received...
Jacobio Pharma Receives RMB 172 Million Milestone Payment from Allist Pharmaceuticals
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced the receipt of...
Apeloa Pharmaceutical Partners with Biocre Tech to Boost Pharmaceutical Innovation
Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a pharmaceutical company based in China, has entered into...
FDA Approves Cobenfy as Novel Schizophrenia Treatment with First-in-Decades Mechanism
The U.S. Food and Drug Administration (FDA) has granted official approval to Cobenfy (KarXT, xanomeline...
Hunan Province Includes Fertility Treatments in Medical Insurance Coverage from October 2024
The Hunan Healthcare Security Administration has issued a notification to include specific assisted reproductive medical...